{"result": "(\"entity\"<|>EASTELL R<|>PERSON<|>Eastell R is an author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>ROSEN CJ<|>PERSON<|>Rosen CJ is an editor and author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>BLACK DM<|>PERSON<|>Black DM is an author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>CHEUNG AM<|>PERSON<|>Cheung AM is an author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>MURAD MH<|>PERSON<|>Murad MH is an author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>SHOBACK D<|>PERSON<|>Shoback D is an author of the clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc. is a medical resource providing clinical information, including guidelines on the management of various health conditions.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>ELSEVIER<|>ORGANIZATION<|>Elsevier is a publishing company known for its medical textbooks and journals, including the Williams Textbook of Endocrinology.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is a city in Pennsylvania, USA, where Elsevier is based.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>EVENT<|>Williams Textbook of Endocrinology is a comprehensive medical textbook covering various aspects of endocrinology.)\n##\n(\"relationship\"<|>EASTELL R<|>UPTODATE INC<|>Eastell R contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>ROSEN CJ<|>UPTODATE INC<|>Rosen CJ contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>BLACK DM<|>UPTODATE INC<|>Black DM contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>CHEUNG AM<|>UPTODATE INC<|>Cheung AM contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>MURAD MH<|>UPTODATE INC<|>Murad MH contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>SHOBACK D<|>UPTODATE INC<|>Shoback D contributed to the clinical practice guideline published by UpToDate Inc.<|>7)\n##\n(\"relationship\"<|>EASTELL R<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Eastell R is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>ROSEN CJ<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Rosen CJ is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>BLACK DM<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Black DM is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>CHEUNG AM<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Cheung AM is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>MURAD MH<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Murad MH is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>SHOBACK D<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>Shoback D is an author of the Williams Textbook of Endocrinology.<|>6)\n##\n(\"relationship\"<|>UPTODATE INC<|>ELSEVIER<|>UpToDate Inc. provides clinical guidelines that may reference works published by Elsevier.<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: .\nB. La hipomagnesemia se asocia a hipercalcemia.\nC. La vitamina D junto al calcio es una medicación coste-efectiva en la prevención y tratamiento de la osteoporosis.\nD. El hipoparatiroidismo posquirúrgico puede ser transitorio.\n\n### COMENTARIO\n\nLa causa más frecuente de hipocalcemia crónica es el hipoparatiroidismo posquirúrgico. Puede ocurrir después de la extirpación de todo el tejido paratiroideo durante una tiroidectomía y una disección cervical radical por cáncer o después de una interrupción accidental de la vascularización de las glándulas paratiroides. Este hipoparatiroidismo puede ser transitorio, frecuentemente después de la paratiroidectomía por lesión reversible de las glándulas normales restantes.\n\nEl aumento del consumo de calcio disminuye el hiperparatiroidismo secundario observado a menudo al avanzar la edad y puede incrementar la mineralización del hueso recién formado. La ingesta óptima de calcio y vitamina D es incierta. En mujeres posmenopáusicas con osteoporosis se recomiendan 1.200 mg de calcio/día (dieta más suplemento si es necesario) y 800 UI/día de vitamina D. Aunque varios ensayos han informado de un efecto beneficioso del calcio o calcio más vitamina D sobre la densidad ósea en mujeres posmenopáusicas y hombres mayores, los datos sobre las tasas de fractura son más variables. Sin embargo, un metaanálisis reciente demostró un aumento escaso, pero uniforme de la DMO y una disminución de las fracturas no vertebrales con 1.200 mg de calcio y 800 UI de vitamina D. El beneficio de esta suplementación parece ser mayor entre las personas institucionalizadas u hospitalizadas que en las personas que viven en la comunidad.\n\nLa hipocalcemia es un signo de hipomagnesemia (opción B falsa: respuesta correcta). En pacientes hipomagnesémicos, la hipocalcemia sintomática se asocia casi siempre con niveles de magnesio plasmáticos inferiores a 1 mEq/l. Los pacientes con concentraciones plasmáticas normales de magnesio pueden tener hipocalcemia que mejora con la terapia con magnesio, posiblemente debido al agotamiento del magnesio celular.\n\nReferencias:\n- Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104:1595-622.\n- Goltzman D. Etiology of hypocalcemia in adults. Rosen CJ, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 7 de junio de 2019).\n- Goltzman D. Diagnostic approach to hypocalcemia. Rosen CJ, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 7 de junio de 2019).\n- Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.\n\n## 10 Indique cuál de los siguientes tipos de pseudohipoparatiroidismo no se asocia a otras resistencias hormonales:\n\nA. Pseudopseudohipoparatiroidismo.\nB. Pseudohipoparatiroidismo 1a.\nC. Pseudohipoparatiroidismo 1b.\nD. Pseudohipoparatiroidismo 1c.\n\n## 11 Indique cuál de los siguientes tipos de pseudohipoparatiroidismo no presenta características clínicas de osteodistrofia hereditaria de Albright:\n\nA. Pseudopseudohipoparatiroidismo.\nB. Pseudohipoparatiroidismo 1a.\nC. Pseudohipoparatiroidismo 1b.\nD. Pseudohipoparatiroidismo 1c.\n---\n# METABOLISMO FOSFOCÁLCICO, TUMORES NEUROENDOCRINOS Y MEN\n\n## COMENTARIO\n\nEl pseudohipoparatiroidismo, resistencia a la acción de PTH en el riñón y/o el hueso, puede ser idiopático o hereditario. Se caracteriza por hipocalcemia, hiperfosfatemia y elevación de la PTH. Hay dos tipos principales:\n\nTipo 1: respuesta anómala fosfatúrica y de AMPc a la PTH. Hay varios subtipos causados por mutaciones de GNAS1 (guanine nucleotide binding protein, alpha stimulating activity polypeptide 1), un gen que codifica la subunidad α de la proteína G que se une al receptor PTH/PTHrP. Estas mutaciones genéticas dan como resultado la incapacidad de la proteína G para activar la adenil-ciclasa tras la unión de la PTH a su receptor. La activación de la adenil\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}